Powerful Intelligence for Dealmakers
The following sample deal entries offer an insight into the level of detail you can expect when subscribing to Current Agreements.
Nicox and Ocumension Therapeutics have entered into an exclusive license agreement for the development and commercialization of Nicox's product candidate, NCX 470 [more(/q/5FrVWgqInymsX5qvr6MTeK)
NantWorks and Sorrento Therapeutics have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens more
Exclusive license agreement where LFB USA granted us an exclusive, worldwide license (or sub-license with respect to third-party in-licensed intellectual property) to develop and commercialize rhAAT worldwide under any intellectual property owned by or licensed to LFB USA more